

CURRICULUM VITAE

Abbas Jamali

Ph.D in Medical Virology

Assistant Professor

Influenza and other Respiratory Viruses

Pasteur Institute of Iran, Tehran, Iran.

Phone #: +98 (21)64112176

Fax #: +98 (21)66496517

Cell #: +912-8446267

e-mail : jamali@pasteur.ac.ir, jamali2004@gmail.com

Education:

3.2009 - 8.2009 Complementary course, Virosome technology, Department of Virology,
Groningen University, The Netherlands

2005-2010 Ph.D. in Medical Virology, Tarbiat Modarres University, Tehran, Iran.

2002-2005 M.Sc. in Medical Virology, Tarbiat Modarres University, Tehran, Iran.

Knowledge base company:

Pars Vaccine Technology Co. CEO,
Product oily adjuvants for killed vaccines

Honors and Awards:

2012 First Prize Winner, Young Researcher, Research Festival of Pasteur Institute of Iran

2010 Registration Fee Award from The European Society of Clinical Microbiology and
Infectious Diseases to attend Postgraduate Education Course "An infection that will never be
out of date: Influenza" which will be held in Istanbul-TURKEY

2008 Travel Award from The International Union of Microbiological Societies (IUMS)
as young scientific to attend the IUMS Congress (XIV International congress of Virology)

2005 First ranked in PhD entrance exam, Tarbiat Modarres University.

Employment History:

- 2011-now Assistant Professor, Virology Dept, Pasteur Institute of Iran
2012-2015 Head of Biotechnology Incubation Center, Pasteur Institute of Iran-Tehran
2012-2015 Technology Manager, Pasteur Institute of Iran. Tehran, Iran

Research project director:

1. **Co-encapsulation of influenza vaccine and CpG ODN motifs into chitosan nanoparticle and evaluation of a dose sparing for influenza vaccine in mice model.**
2. **Construction of a Recombinant Newcastle Disease Virus Vector containing Respiratory Syncytial Virus Fusion gene.**
3. **Reconstituting a recombinant chimeric influenza virosome associated with VSV as a delivery system for insect and mammalian cell lines**

Professional Activities:

2002 - present Member of Iranian Society of Virology

Workshops:

The Sixth Summer School, Pasteur Institute of Iran, Influenza Lab Research, 2015
The Fifth Summer School, Pasteur Institute of Iran, Influenza Lab Research, 2014
The Fourth Summer School, Pasteur Institute of Iran, Influenza Lab Research, 2013
The Third Summer School, Pasteur Institute of Iran, Influenza Lab Research, 2012
The Second Summer School, Pasteur Institute of Iran, Influenza Lab Research, 2011
The First Summer School, Pasteur Institute of Iran, Influenza Lab Research, 2010

Publications (Articles):

1. Molecular epidemiology of the hemagglutinin gene of prevalent influenza virus A/H1N1/pdm09 among patient in Iran. Mohebbi A, Fotouhi F, Jamali A, Yaghobi R, Farahmand B, Mohebbi R. *Virus Res.* 2019 Jan 2;259:38-45. doi: 10.1016/j.virusres.2018.10.001. Epub 2018 Oct 15. PMID: 30336188
2. Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts. Salimi V, Mirzaei H, Ramezani A, Tahamtan A, Jamali A, Shahabi S, Golar M, Minaei B, Gharagozlou MJ, Mahmoodi M, Bont L, Shokri F, Mokhtari-Azad T. *Med Microbiol Immunol.* 2018 Nov;207(5-6):345. doi: 10.1007/s00430-018-0562-1. PMID: 30244293
3. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model. Sadati SF, Jamali A, Abdoli A, Abedi-Valugerdi M, Gholami S, Alipour S, Soleymani S, Kheiri MT, Atyabi F. *Pathog Dis.* 2018 Nov 1;76(8). doi: 10.1093/femspd/fty070. PMID: 30184220
4. IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo. Khodamoradi S, Shenagari M, Kheiri MT, Sabahi F, Jamali A, Heidari A, Ashrafkhani B. *Arch Virol.* 2018 Apr;163(4):877-886. doi: 10.1007/s00705-017-3682-9. Epub 2017 Dec 21. PMID: 29270718

5. Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA. Jamali A, Mottaghitalab F, Abdoli A, Dinarvand M, Esmailie A, Kheiri MT, Atyabi F. *Drug Deliv Transl Res.* 2018 Feb;8(1):12-20. doi: 10.1007/s13346-017-0426-z. PMID: 29063498

6. Autophagy induction regulates influenza virus replication in a time-dependent manner. Feizi N, Mehrbod P, Romani B, Soleimanjahi H, Bamdad T, Feizi A, Jazaeri EO, Targhi HS, Saleh M, Jamali A, Fotouhi F, Nargesabad RN, Abdoli A. *J Med Microbiol.* 2017 Apr;66(4):536-541

7. Suppressive Effects of Chronic Stress on Influenza Virus Protection after Vaccination with Plasmid DNA-Encoded Nucleoprotein. Nezam FS, Hosseini SM, Kheiri MT, Abdoli A, Memarnejadian A, Shenagari M, Gholami S, Sohani H, Rahmatollahi H, Jamali A. *Neuroimmunomodulation.* 2015;22(5):322-7.

8. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice. Abdoli A, Soleimanjahi H, Tavassoti Kheiri M, Jamali A, Mazaheri V, Abdollahpour Alitappeh M. *Pathog Dis.* 2014 Dec;72(3):197-207

9. Determining influenza virus shedding at different time points in madin-darby canine kidney cell line. Abdoli A, Soleimanjahi H, Tavassoti Kheiri M, Jamali A, Jamaati A. *Cell J.* 2013 Summer;15(2):130-5.

10. Reconstruction of H3N2 influenza virus based virosome in-vitro. Abdoli A, Soleimanjahi H, Kheiri MT, Jamali A, Sohani H, Abdoli M, Rahmatollahi HR. *Iran J Microbiol.* 2013 Jun;5(2):166-71.

11. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Jamali A, Holtrop M, de Haan A, Hashemi H, Shenagari M, Memarnejadian A, Roohvand F, Sabahi F, Kheiri MT, Huckriede A. *Immunol Lett.* 2012 Nov-Dec;148(1):77-82.
12. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Kheiri MT, Jamali A, Shenagari M, Hashemi H, Sabahi F, Atyabi F, Saghiri R. *Antiviral Res.* 2012 Sep;95(3):229-36.
13. Withdrawal from morphine reduces cell-mediated immunity against herpes simplex virus generated by natural immunization. Jamali A, Soleimanjahi H, Moin M, Mahdavi M, Hashemi H, Sabahi F, Hassan ZM, Bamdad T. *Neuroimmunomodulation.* 2012;19(4):229-34.
14. A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. Jamali A, Sabahi F, Bamdad T, Hashemi H, Mahboudi F, Kheiri MT. *Clin Vaccine Immunol.* 2010 Apr;17(4):683-7.
15. Evaluation of apoptotic and anti-apoptotic genes on efficacy of DNA vaccine encoding glycoprotein B of Herpes Simplex Virus type 1. Parsania M, Bamdad T, Hassan ZM, Kheirandish M, Pouriayevali MH, Sari RD, Jamali A. *Immunol Lett.* 2010 Feb 16;128(2):137-42.
16. Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: a comparative approach to conventional DNA vaccine. Hashemi H, Bamdad T, Jamali A, Pouyanfard S, Mohammadi MG. *J Virol Methods.* 2010 Feb;163(2):440-4.
17. Acute morphine administration reduces cell-mediated immunity and induces reactivation of latent herpes simplex virus type 1 in BALB/c mice. Mojadadi S, Jamali A, Khansarinejad B, Soleimanjahi H, Bamdad T. *Cell Mol Immunol.* 2009 Apr;6(2):111-6.
18. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, Soleimanjahi H, Motazakker M, Shahabi S. *Int Immunol.* 2009 Mar;21(3):217-25.

19. Acute morphine administration reduces white blood cells' capability to induce innate resistance against HSV-1 infection in BALB/c mice. Jamali A, Bamdad T, Soleimanjahi H, Pakdel FG, Arefian E. *Neuroimmunomodulation*. 2007;14(1):16-23.
20. 14. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Jamali A, Mahdavi M, Shahabi S, Hassan ZM, Sabahi F, Javan M, Farsani MJ, Parsania M, Bamdad T. *Microb Pathog*. 2007 Nov-Dec;43(5-6):217-23.
21. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge. Jamali A, Roostaei MH, Soleimanjahi H, Ghaderi Pakdel F, Bamdad T. *Comp Immunol Microbiol Infect Dis*. 2007 Mar;30(2):71-80.

Reviewer for journals

Vaccine, Elsevier